Pelcitoclax (APG-1252) is a potent Bcl-2/Bcl-xl inhibitor with antineoplastic and pro-apoptotic effects. In Vitro APG-1252 changes to the reactive metabolite named APG-1252-M1, which has remarkable antitumor effects in acute myeloid leukemia. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Pelcitoclax (APG-1252; 25-100 mg/kg; i.v.; once a day; for 10 days) treatment inhibits xenograft tumor growth more obviously than the other groups . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: BALB/c athymic nude mice (male, 4-6weeks) injected with N87 cells Dosage: 25 mg/kg, 50 mg/kg, and 100 mg/kg Administration: Intravenous injection; once a day; for 10 days Result: Inhibited xenograft tumor growth more obviously than the other groups. Form:Solid